Kailera Therapeutics, Inc.

NASDAQ:KLRA

Biotechnology

Healthcare
$11.79 +2.66%

+$0.51 today

Market cap
$1.53B
Beta
0.00
52W Low $18.50High $28.23

Volume 0.42M

Average 0.80M

Returns on capital

Kailera Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

41.8%

avg 41.8%

ROIC

-24.5%

avg -24.5%

ROA

-21.5%

avg -21.5%

Analysis

ROE is currently the strongest return metric at 41.8% versus its period average of 41.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jamie Beth Coleman

Chief Commercial OfficerUSD 911.28K4875.00K0.06%

Ronald C. Renaud Jr.

President, CEO & DirectorUSD 863.87K5738.09K0.03%

Paul Douglas Burgess

Chief Operating & Business OfficerUSD 670.19K52——

Kathleen Tregoning

Chief Corporate Affairs Officer—55175.00K0.14%

Corey Manchester

Treasurer————

Scott Wasserman

Chief Medical Officer—56——

Maura Gavaghan

Vice President of Corporate Communications & Investor Relations————

Scott Akamine

Chief Legal Officer & Secretary—4160.00K0.05%

Paula A. Cloghessy SHRM-SCP SPHR

Chief People Officer—54——

Douglas W. Pagan

Chief Financial Officer—54100.00K0.08%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

5

$326.75M

Sells

0

$0.00

Net Transaction Value

+$326.75M

Net buying

Most Active

BAIN CAPITAL INVESTORS LLC

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 20, 26

BAIN CAPITAL INVESTORS LLC

Indirect

Buy$134.4M
Apr 20, 26

Koppel Adam

Indirect

Buy$25M
Apr 20, 26

Bain Capital Life Sciences Investors, LLC

Indirect

Buy$25M
Apr 20, 26

Kaplan Andrew T.

Indirect

Buy$134.4M
Apr 20, 26

RTW INVESTMENTS, LP

Indirect

Buy$8M

Summary

Insiders reported 5 buys worth $326.75M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $326.75M. BAIN CAPITAL INVESTORS LLC was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Kailera Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about KLRA's management, answered from reported figures.

Who manages KLRA?

Kailera Therapeutics, Inc. (KLRA) lists 10 active executives. The top listed executive is Kathleen Tregoning, Chief Corporate Affairs Officer.

Are KLRA insiders buying or selling?

Recent insider activity shows net buying of $350.79M.